Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

A new era of treating advanced lung cancer is upon us.

Weiss GJ.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S202-S205. doi: 10.21037/tlcr.2018.07.03. No abstract available.

2.

Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ.

PLoS One. 2018 Jun 28;13(6):e0200224. doi: 10.1371/journal.pone.0200224. eCollection 2018.

3.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

4.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

5.
6.

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V.

Invest New Drugs. 2018 Feb;36(1):96-102. doi: 10.1007/s10637-017-0525-1. Epub 2017 Nov 8.

PMID:
29119276
7.

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.

8.

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.

Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D.

ESMO Open. 2017 Feb 23;1(6):e000154. doi: 10.1136/esmoopen-2016-000154. eCollection 2016.

9.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK.

Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20.

PMID:
28726132
10.

Prophylactic cranial irradiation in small-cell lung cancer.

Weiss GJ, Lohinai Z.

Lancet Oncol. 2017 Jul;18(7):e367. doi: 10.1016/S1470-2045(17)30405-9. No abstract available.

PMID:
28677570
11.

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V.

Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6.

12.

A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.

Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG.

PLoS One. 2017 Jun 6;12(6):e0179170. doi: 10.1371/journal.pone.0179170. eCollection 2017.

13.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

14.

Using circulating cell-free DNA to monitor personalized cancer therapy.

Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD.

Crit Rev Clin Lab Sci. 2017 May;54(3):205-218. doi: 10.1080/10408363.2017.1299683. Epub 2017 Apr 10. Review.

PMID:
28393575
15.

Reviewing concomitant medications for participants in oncology clinical trials.

McGahey KE, Weiss GJ.

Am J Health Syst Pharm. 2017 Apr 15;74(8):580-586. doi: 10.2146/ajhp151052.

PMID:
28389457
16.

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W Jr, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E.

Clin Cancer Res. 2017 Sep 1;23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.

17.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

18.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
19.

Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.

Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW.

Oncology. 2016;91(6):299-301. Epub 2016 Oct 6. Review.

PMID:
27705967
20.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

21.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.

22.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ.

PLoS One. 2016 Jan 6;11(1):e0144797. doi: 10.1371/journal.pone.0144797. eCollection 2016.

23.

Precision medicine: lessons learned from the SHIVA trial.

Weiss GJ.

Lancet Oncol. 2015 Dec;16(16):e580. doi: 10.1016/S1470-2045(15)00387-3. No abstract available.

PMID:
26678199
24.

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.

Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M.

Cancer Cell. 2015 Oct 12;28(4):500-514. doi: 10.1016/j.ccell.2015.09.003.

25.

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.

Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK.

Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.

26.

Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification].

Weiss GJ, Khemka V.

Onco Targets Ther. 2015 Sep 18;8:2643. doi: 10.2147/OTT.S96038. eCollection 2015. No abstract available.

27.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

28.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

29.

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.

Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J.

Cancer Chemother Pharmacol. 2015 Sep;76(3):587-95. doi: 10.1007/s00280-015-2830-8. Epub 2015 Jul 26.

PMID:
26210682
30.

Influence of Robotic-Assisted Surgery on Readmission Burden.

Weiss GJ.

J Clin Oncol. 2015 Jul 1;33(19):2229. doi: 10.1200/JCO.2015.61.7464. Epub 2015 May 26. No abstract available.

PMID:
26014299
31.

Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.

Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Gingrich SA, Penny RJ, Mallery DW, Morris SM, Thompson EJ, Loesch DM, Khemka V.

Onco Targets Ther. 2015 Apr 24;8:959-67. doi: 10.2147/OTT.S81995. eCollection 2015.

32.

Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers.

Dearing KR, Weiss GJ.

Per Med. 2015 Mar;12(2):155-162. doi: 10.2217/pme.14.54. Epub 2015 Jan 20.

PMID:
29754537
33.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA 3rd, Orlemans EO, Ramanathan RK.

Eur J Cancer. 2014 Nov;50(17):2897-904. doi: 10.1016/j.ejca.2014.07.017. Epub 2014 Sep 25.

PMID:
25262379
34.

Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.

Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL.

PLoS One. 2014 Jul 2;9(7):e100244. doi: 10.1371/journal.pone.0100244. eCollection 2014.

35.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290. Epub 2014 Jun 5.

36.

ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.

Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD.

Radiology. 2014 Aug;272(2):568-76. doi: 10.1148/radiol.14140789. Epub 2014 Jun 2.

PMID:
24885982
37.

Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer.

Dearing KR, Sangal A, Weiss GJ.

World J Clin Oncol. 2014 May 10;5(2):103-13. doi: 10.5306/wjco.v5.i2.103. Review.

38.

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM.

Clin Cancer Res. 2014 Jul 15;20(14):3683-91. doi: 10.1158/1078-0432.CCR-14-0392. Epub 2014 May 7.

39.

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL.

Clin Exp Metastasis. 2014 Aug;31(6):613-23. doi: 10.1007/s10585-014-9653-6. Epub 2014 Apr 8.

PMID:
24710956
40.

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK.

Cancer Chemother Pharmacol. 2014 May;73(5):931-41. doi: 10.1007/s00280-014-2424-x. Epub 2014 Mar 8.

41.

Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, Sima C, LoBello J, Weiss GJ, Tran NL.

Mol Cancer Res. 2014 Apr;12(4):550-9. doi: 10.1158/1541-7786.MCR-13-0458. Epub 2014 Jan 27.

42.

Molecular characterization may be of PARAMOUNT importance.

Dearing KR, Weiss GJ.

J Clin Oncol. 2014 Feb 10;32(5):481-2. doi: 10.1200/JCO.2013.53.3893. Epub 2014 Jan 6. No abstract available.

PMID:
24395858
43.

Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC.

Tran JQ, Dranikov A, Iannucci A, Wagner WP, LoBello J, Allen J, Weiss GJ.

Lung Cancer Int. 2014;2014:853158. doi: 10.1155/2014/853158. Epub 2014 Jul 9.

44.

A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges.

Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW.

PLoS One. 2013 Oct 30;8(10):e76438. doi: 10.1371/journal.pone.0076438. eCollection 2013.

45.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ.

J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.

46.

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion.

Weiss GJ, Liman AK, Allen J, Cheung PY, Kukunoor RN.

Case Rep Med. 2013;2013:874836. doi: 10.1155/2013/874836. Epub 2013 Sep 19.

47.

CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.

Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16868-73. doi: 10.1073/pnas.1306358110. Epub 2013 Sep 30.

48.

Long insert whole genome sequencing for copy number variant and translocation detection.

Liang WS, Aldrich J, Tembe W, Kurdoglu A, Cherni I, Phillips L, Reiman R, Baker A, Weiss GJ, Carpten JD, Craig DW.

Nucleic Acids Res. 2014 Jan;42(2):e8. doi: 10.1093/nar/gkt865. Epub 2013 Sep 25.

49.

Examining the effect of teleconferences on oncology phase 1 trials.

McKane A, Sima C, Fleck S, Weiss GJ.

J Cancer. 2013 Jul 4;4(6):464-7. doi: 10.7150/jca.6626. Print 2013.

50.

Molecular determinants of lung cancer metastasis to the central nervous system.

Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL.

Transl Lung Cancer Res. 2013 Aug;2(4):273-83. doi: 10.3978/j.issn.2218-6751.2013.03.12. Review.

Supplemental Content

Loading ...
Support Center